InsidersTradesSigma
Cyteir Therapeutics, Inc.: insider trades · United States · SEC (Form 4)
SEC:cyteir-therapeutics-inc-72cf9fUS·SEC (Form 4)
Discover the full directors' dealings record of Cyteir Therapeutics, Inc., a listed equity based in United States. Shares are listed on US US, under the authority of SEC (Form 4). The latest transaction was reported on 16 May 2022 — Acquisition. Among the most active insiders: Zakrzewski Joseph S. All data is accessible without an account.
23
Insider Decl.
0
Thresholds
€152,954
9 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
Last declaration on 16 May 2022
Declarations23 total
Executives▲Purchase33SEC
€1,152743 shares@ €1.55110.9% of flow
Common Stock
SEC:0001209191-22-029135:0·
Ideal exit: 6 Feb 2023 (T+270)
Executives▲Purchase40SEC
€88,65249,406 shares@ €1.794466.2% of flow
Common Stock
SEC:0001209191-22-028574:0·
Ideal exit: 4 Feb 2023 (T+270)
Executives▲Purchase35SEC
€18,98810,000 shares@ €1.8988100.0% of flow
Common Stock
SEC:0001209191-22-028578:0·
Ideal exit: 4 Feb 2023 (T+270)
Executives▲Purchase18SEC
€1,742200 shares@ €8.71227.9% of flow
Common Stock
SEC:0000899243-21-049973·
Ideal exit: 19 Sept 2022 (T+270)
Executives▲Purchase21SEC
€1,742200 shares@ €8.71221.3% of flow
Common Stock
SEC:0000899243-21-049973:0·
Ideal exit: 19 Sept 2022 (T+270)
Executives▲Purchase16SEC
€1,743200 shares@ €8.7177.9% of flow
Common Stock
SEC:0000899243-21-049198·
Ideal exit: 13 Sept 2022 (T+270)
Executives▲Purchase19SEC
€1,743200 shares@ €8.7171.3% of flow
Common Stock
SEC:0000899243-21-049198:0·
Ideal exit: 13 Sept 2022 (T+270)
Executives▲Purchase21SEC
€18,5952,000 shares@ €9.297484.2% of flow
Common Stock
SEC:0000899243-21-048432·
Ideal exit: 11 Sept 2022 (T+270)
Executives▲Purchase16SEC
€18,5952,000 shares@ €9.297413.9% of flow
Common Stock
SEC:0000899243-21-048432:0·
Ideal exit: 11 Sept 2022 (T+270)
Executives●C2SEC
3,259,025 shares
Common Stock
SEC:0001209191-21-042724:0·
23 of 23 declarations
